0001104659-23-083567.txt : 20230724
0001104659-23-083567.hdr.sgml : 20230724
20230724210848
ACCESSION NUMBER: 0001104659-23-083567
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230721
FILED AS OF DATE: 20230724
DATE AS OF CHANGE: 20230724
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Oh Chad
CENTRAL INDEX KEY: 0001882166
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40021
FILM NUMBER: 231106263
MAIL ADDRESS:
STREET 1: C/O AEON BIOPHARMA, INC.
STREET 2: 4040 MACARTHUR BOULEVARD, SUITE 250
CITY: NEWPORT BEACH
STATE: CA
ZIP: 92660
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AEON Biopharma, Inc.
CENTRAL INDEX KEY: 0001837607
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 853940478
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 PARK PLAZA
STREET 2: SUITE 1750
CITY: IRVINE
STATE: CA
ZIP: 92614
BUSINESS PHONE: (949) 354-6499
MAIL ADDRESS:
STREET 1: 5 PARK PLAZA
STREET 2: SUITE 1750
CITY: IRVINE
STATE: CA
ZIP: 92614
FORMER COMPANY:
FORMER CONFORMED NAME: Priveterra Acquisition Corp.
DATE OF NAME CHANGE: 20201222
4
1
tm2321918-10_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-07-21
0
0001837607
AEON Biopharma, Inc.
AEON
0001882166
Oh Chad
5 PARK PLAZA, SUITE 1750
IRVINE
CA
92614
0
1
0
0
Chief Medical Officer
0
Stock Option
10.00
2023-07-21
4
A
0
145588
0
A
2031-08-23
Common Stock
145588
145588
D
Stock Option
10.00
2023-07-21
4
A
0
115151
0
A
2032-03-09
Common Stock
115151
115151
D
Restricted Stock Units
2023-07-21
4
A
0
100428
0
A
Common Stock
100428
100428
D
On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. ("Merger Sub") and AEON Biopharma, Inc. ("AEON"), upon consummation of the transactions contemplated thereby (the "Effective Time"), each issued and outstanding share of common stock of AEON ("AEON common stock") was automatically cancelled and converted into approximately 2.328 (the "Exchange Ratio") shares of Class A common stock of the Issuer.
At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an "AEON Option") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share.
Represents an award of stock options on August 23, 2021, which vests in four yearly installments from May 31, 2021, subject to the reporting person's continued service through the applicable vesting date.
Represents an award of stock options on March 9, 2022, which vests in four yearly installments from March 9, 2022, subject to the reporting person's continued service through the applicable vesting date.
At the Effective Time, each outstanding award of restricted stock unit ("RSU") representing the contingent right to receive shares of AEON common stock (each an "AEON RSU") was automatically cancelled and converted into an RSU representing the contingent right to receive a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON RSU multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share.
Represents an award of RSUs on April 26, 2023, which vests in four yearly installments from April 26, 2023, subject to the reporting person's continued service through the applicable vesting date.
/s/ Alexander Wilson, Attorney-in-Fact
2023-07-24